Literature DB >> 1312162

Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal.

R R Griffiths1, C A Sannerud, N A Ator, J V Brady.   

Abstract

This study examined in baboons various behavioral effects of zolpidem, a short-acting imidazopyridine hypnotic which has selectivity for subtypes of the benzodiazepine receptor. Intravenous drug self-injection was studied under a fixed-ratio 80- or 160-response schedule with a 3-hr timeout after each injection. Maximal rates of self-injection maintained by zolpidem (0.01-1 mg/kg) were consistently higher than those maintained by vehicle and the benzodiazepine hypnotic triazolam. Substitution of vehicle after about 2 weeks of zolpidem self-injection (7-8 mg/kg/day) resulted in a time-limited suppression of food pellet intake, indicating a drug withdrawal effect. In a drug discrimination study, baboons were trained to discriminate either lorazepam (1.8 mg/kg p.o.) or pentobarbital (10 mg/kg p.o.) from the no-drug condition. Zolpidem (0.1-18 mg/kg p.o.) occasioned both lorazepam- and pentobarbital-appropriate responding (greater than 80%) in a dose-dependent manner. In a final experiment, zolpidem (3.2 or 5.6 mg/kg i.m.) produced ataxia and sedation that progressively decreased over 7 consecutive days of administration. The withdrawal, discriminative stimulus effects and tolerance shown with zolpidem were similar to those shown previously with benzodiazepines under similar conditions. The rates of self-injection of zolpidem were similar to those maintained by intermediate duration barbiturates (e.g., pentobarbital) and higher than those maintained by 11 benzodiazepines studied previously under similar conditions. Further research on the reinforcing effects of zolpidem may provide useful insights into mechanisms underlying the maintenance of behavior by compounds acting through the benzodiazepine receptor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312162

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  29 in total

Review 1.  Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey.

Authors:  Caroline Victorri-Vigneau; Eric Dailly; Gwenaëlle Veyrac; Pascale Jolliet
Journal:  Br J Clin Pharmacol       Date:  2007-02-23       Impact factor: 4.335

2.  GABAA Receptor Subtypes and the Reinforcing Effects of Benzodiazepines in Remifentanil-Experienced Rhesus Monkeys.

Authors:  Lais F Berro; James K Rowlett
Journal:  Drug Alcohol Depend       Date:  2020-05-25       Impact factor: 4.492

3.  Effects of triazolam on drinking in baboons with and without an oral self-administration history: a reinstatement phenomenon.

Authors:  M A Kautz; N A Ator
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

Review 4.  The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.

Authors:  Amanda C Fitzgerald; Brittany T Wright; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

Review 5.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

Review 6.  Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.

Authors:  K J Holm; K L Goa
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

7.  Neural basis of benzodiazepine reward: requirement for α2 containing GABAA receptors in the nucleus accumbens.

Authors:  Elif Engin; Konstantin I Bakhurin; Kiersten S Smith; Rochelle M Hines; Lauren M Reynolds; Wannan Tang; Rolf Sprengel; Stephen J Moss; Uwe Rudolph
Journal:  Neuropsychopharmacology       Date:  2014-02-19       Impact factor: 7.853

Review 8.  Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.

Authors:  Stephanie C Licata; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2008-01-12       Impact factor: 3.533

9.  Antagonism of triazolam self-administration in rhesus monkeys responding under a progressive-ratio schedule: In vivo apparent pA2 analysis.

Authors:  Bradford D Fischer; Donna M Platt; Sundari K Rallapalli; Ojas A Namjoshi; James M Cook; James K Rowlett
Journal:  Drug Alcohol Depend       Date:  2015-10-30       Impact factor: 4.492

Review 10.  Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.

Authors:  Masaomi Miyamoto
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.